These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 142313)

  • 1. A simple and practical method for isolation of an early plasmin degradation product of human fibrinogen.
    Takagi K; Kawai T
    Thromb Haemost; 1977 Jun; 37(3):464-70. PubMed ID: 142313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrin and fibrinogen proteolysis products: comparison between gel filtration and SDS polyacrylamide electrophoresis analysis.
    Alkjaersig N; Davies A; Fletcher A
    Thromb Haemost; 1977 Aug; 38(2):524-5. PubMed ID: 145666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The role of DL and DH degradation products in the reactions of the plasmin hydrolysis of fibrinogen and fibrin].
    Rozenfel'd MA; Leonova VB; Khavkina LS
    Izv Akad Nauk SSSR Biol; 1991; (3):334-42. PubMed ID: 1835465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Degradation of human fibrinogen by plasmin: isolation and partial characterization of an early degradation product.
    Regañon E; Aznar J; Vila V
    Haemostasis; 1978; 7(1):26-34. PubMed ID: 147811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioimmunoassay of an early plasmin degradation product of human fibrinogen, "fragment A", and its clinical application.
    Takagi K; Kawai T
    Thromb Haemost; 1978 Feb; 39(1):1-11. PubMed ID: 148116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Electrophoretic demonstration of high molecular weight fibrin degradation products persisting in chronic subdural hematomas.
    Toyosawa M; Kashiwagi S; Pei W; Fujisawa H; Ito H; Nakamura K
    Electrophoresis; 1997 Jan; 18(1):118-21. PubMed ID: 9059832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progressive exposure of E-neoantigen associated with degradation of crosslinked fibrin by plasmin in vitro.
    Stegnar M; Chen JP
    Thromb Haemost; 1984 Dec; 52(3):315-20. PubMed ID: 6241755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antifibrinolytic effect of heparin].
    Rozenfel'd MA; Leonova VB; Khavkina LS; Meshkov BB
    Biokhimiia; 1984 Oct; 49(10):1672-8. PubMed ID: 6240283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmic degradation of fibrinogen Paris I.
    Budzynski AZ; Marder VJ
    J Lab Clin Med; 1976 Nov; 88(5):817-25. PubMed ID: 978044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unreliability in the estimation of the molecular weight of fibrinogen degradation products (FDPs) by polyacrylamide/sodium dodecyl sulphate electrophoresis (SDS/PAGE).
    Arocha-Piñango CL; Perales J; Carvajal Z
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1985; 112(5):737-41. PubMed ID: 2416650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of NH2-terminal fibrinogen B beta fragments from N-DSK of human fibrinogen.
    Birken S; Agosto G; Lahiri B; Canfield R
    Thromb Haemost; 1984 Feb; 51(1):16-21. PubMed ID: 6232727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A subfraction of fragment D isolated from a plasmin hydrolysate of human fibrinogen.
    Hörmann H
    Hoppe Seylers Z Physiol Chem; 1975 Dec; 356(12):1947-53. PubMed ID: 129428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis.
    Stucki B; Schmutz P; Schmid L; Haeberli A; Lämmle B; Furlan M
    Thromb Haemost; 1999 Feb; 81(2):268-74. PubMed ID: 10064005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Electrophoretic fractions and NH2-terminal amino acids of high-molecular tryptic fragments of fibrinogen and fibrin].
    Lugovskoĭ EV; Pozdniakova TM; Varetskaia TV; Derzskaia SG; Tolstykh VM
    Ukr Biokhim Zh; 1976; 48(6):743-9. PubMed ID: 1014141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrin detected in plasma of patients with disseminated intravascular coagulation by fibrin-specific antibodies consists primarily of high molecular weight factor XIIIa-crosslinked and plasmin-modified complexes partially containing fibrinopeptide A.
    Pfitzner SA; Dempfle CE; Matsuda M; Heene DL
    Thromb Haemost; 1997 Sep; 78(3):1069-78. PubMed ID: 9308756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Differentiation of fibrinolysis and fibrinogenolysis by analysis of FDP fragments].
    Okumura N; Furuwatari C; Ishikawa S; Furihata K; Katsuyama T; Kanai M; Nakahata T; Saitoh H
    Rinsho Byori; 1992 Jul; 40(7):789-94. PubMed ID: 1507499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Degradation pathway of fibrinogen by plasmin.
    Budzynski AZ; Marder VJ
    Thromb Haemost; 1977 Dec; 38(4):793-800. PubMed ID: 146273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fibrinogen fragment D - inhibitor of fibrinolytic processes].
    Rozenfel'd MA; Fateeva LA; Gontar' ID
    Biokhimiia; 1983 Jul; 48(7):1135-40. PubMed ID: 6225469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunochemical discrimination of leukocyte elastase from plasmic degradation products of fibrinogen.
    Plow EF; Gramse M; Havemann K
    J Lab Clin Med; 1983 Dec; 102(6):858-69. PubMed ID: 6227673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A model of proteolysis of the fragment DH (95 kD) of the fibrinogen molecule].
    Litvinovich SV; Medved' LV
    Mol Biol (Mosk); 1988; 22(4):934-43. PubMed ID: 3054505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.